{
  "symbol": "REGN",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2048,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.481
  },
  "top_positive": [
    {
      "sent": "Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 Dupixent and Kevzara net product sales $ 4,496.8 $ 3,666.1 $ 8,278.8 $ 6,837.0 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,496.7 $ 1,149.2 $ 2,676.9 $ 2,075.1 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (a) (214.6) (160.9) (376.7) (282.8) Regeneron's share of profits $ 1,282.1 $ 988.3 $ 2,300.2 $ 1,792.3 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 29% 27% 28% 26% (a) See \"Collaboration, License, and Other Agreements - Sanofi\" above for additional details on our contingent reimbursement obligation The increase in our share of profits for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024, was driven by higher profits associated with Dupix\nurrently in Phase 3 clinical development in China) became effective.",
      "score": 0.9847
    },
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 977.7 $ 907.8 $ 1,835.5 $ 1,757.2 Regeneron's share of collaboration profit from sales outside the United States $ 399.9 $ 369.0 $ 733.5 $ 719.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.5) (16.0) (32.8) (32.6) Regeneron's share of profits $ 383.4 $ 353.0 $ 700.7 $ 686.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% 38% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue increased for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024.",
      "score": 0.9846
    },
    {
      "sent": "Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 Dupixent and Kevzara net product sales $ 4,496.8 $ 3,666.1 $ 8,278.8 $ 6,837.0 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,496.7 $ 1,149.2 $ 2,676.9 $ 2,075.1 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (a) (214.6) (160.9) (376.7) (282.8) Regeneron's share of profits $ 1,282.1 $ 988.3 $ 2,300.2 $ 1,792.3 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 29% 27% 28% 26% (a) See \"Collaboration, License, and Other Agreements - Sanofi\" above for additional details on our contingent reimbursement obligation The increase in our share of profits for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024, was driven by higher profits associated with Dupixent sales.",
      "score": 0.9814
    }
  ],
  "top_negative": [
    {
      "sent": "The side effects previously reported for Dupixent include severe allergic reactions, eye problems (including eye pain or changes in vision), joint aches and pain, parasitic (helminth) infections, facial rash or redness, and inflammation of blood vessels in the skin; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea.",
      "score": -0.9628
    },
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "Other Regulatory and Litigation Risks If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    }
  ],
  "forward_snippets": [
    "Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures .",
    "January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements.",
    "Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures .",
    "January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements.",
    "guidance related to improvements to income tax disclosures ."
  ],
  "curated_text": "Symbol: REGN. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 Dupixent and Kevzara net product sales $ 4,496.8 $ 3,666.1 $ 8,278.8 $ 6,837.0 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,496.7 $ 1,149.2 $ 2,676.9 $ 2,075.1 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (a) (214.6) (160.9) (376.7) (282.8) Regeneron's share of profits $ 1,282.1 $ 988.3 $ 2,300.2 $ 1,792.3 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 29% 27% 28% 26% (a) See \"Collaboration, License, and Other Agreements - Sanofi\" above for additional details on our contingent reimbursement obligation The increase in our share of profits for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024, was driven by higher profits associated with Dupix\nurrently in Phase 3 clinical development in China) became effective. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 977.7 $ 907.8 $ 1,835.5 $ 1,757.2 Regeneron's share of collaboration profit from sales outside the United States $ 399.9 $ 369.0 $ 733.5 $ 719.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.5) (16.0) (32.8) (32.6) Regeneron's share of profits $ 383.4 $ 353.0 $ 700.7 $ 686.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% 38% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue increased for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024. Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 2025 2024 Dupixent and Kevzara net product sales $ 4,496.8 $ 3,666.1 $ 8,278.8 $ 6,837.0 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,496.7 $ 1,149.2 $ 2,676.9 $ 2,075.1 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (a) (214.6) (160.9) (376.7) (282.8) Regeneron's share of profits $ 1,282.1 $ 988.3 $ 2,300.2 $ 1,792.3 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 29% 27% 28% 26% (a) See \"Collaboration, License, and Other Agreements - Sanofi\" above for additional details on our contingent reimbursement obligation The increase in our share of profits for the three and six months ended June\u00a030, 2025, compared to the same periods in 2024, was driven by higher profits associated with Dupixent sales. Top negative sentences: The side effects previously reported for Dupixent include severe allergic reactions, eye problems (including eye pain or changes in vision), joint aches and pain, parasitic (helminth) infections, facial rash or redness, and inflammation of blood vessels in the skin; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. Other Regulatory and Litigation Risks If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. Forward-looking snippets: Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures . January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements. Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures . January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements. guidance related to improvements to income tax disclosures ."
}